Periodic fever syndromes are a group of conditions in which the body’s immune system triggers recurring episodes of fever and inflammation without any infection. These aren’t caused by bacteria or viruses, and antibiotics do nothing against them. Some are inherited, caused by mutations in genes that regulate inflammation, while others arise without a clear genetic cause. The best-known include familial Mediterranean fever (FMF), TRAPS, cryopyrin-associated periodic syndromes (CAPS), mevalonate kinase deficiency (MKD), and PFAPA syndrome. Despite being individually rare, they collectively affect tens of thousands of people, and the gap between first symptoms and correct diagnosis can stretch for years.
What Makes These Different from Normal Fevers or Autoimmune Diseases
When most people get a fever, their immune system is responding to a pathogen. Periodic fever syndromes skip that step entirely. The inflammation arises from the innate immune system, the older, faster-acting part of your defenses that doesn’t need to “learn” a specific threat. In these conditions, cells like macrophages and neutrophils activate on their own, as if responding to an invader that isn’t there.
This is a different process from what happens in autoimmune diseases like lupus or rheumatoid arthritis. Autoimmune diseases involve the adaptive immune system, where specialized immune cells mistakenly recognize the body’s own tissues as foreign and mount a sustained attack against them.1The Journal of Rheumatology. Autoinflammatory Diseases: A Review In periodic fever syndromes, the problem lies upstream: the innate immune cells themselves are misfiring due to built-in defects, often in the molecular machinery that controls inflammation. The distinction matters because treatments that work for autoimmune diseases often miss the mark entirely for autoinflammatory conditions, and vice versa.
The Four Main Hereditary Periodic Fever Syndromes
Each of the classic hereditary syndromes traces back to a different gene and produces a somewhat distinct pattern of symptoms. All of them, however, share the hallmark of recurrent, seemingly unprovoked episodes of fever alongside inflammation in various organs.
Familial Mediterranean Fever
FMF is the most common hereditary periodic fever syndrome, concentrated among people of Mediterranean descent, including Turkish, Armenian, Arab, and Jewish populations. It is caused by mutations in the MEFV gene, which encodes a protein called pyrin. Episodes typically last one to three days and involve high fever along with intense pain in the abdomen, chest, or joints. Between attacks, people usually feel completely normal.
The standard treatment is colchicine, a decades-old drug that prevents attacks in most patients and, critically, protects against the most feared long-term complication: amyloidosis. Amyloidosis occurs when a protein called serum amyloid A, produced in large quantities during inflammation, gradually deposits in organs, especially the kidneys. In untreated or undertreated FMF, amyloidosis develops in up to roughly 9% of patients.2PubMed Central. Amyloidosis and Glomerular Diseases in Familial Mediterranean Fever Certain MEFV mutations carry more risk than others. Patients who are homozygous for the M694V mutation, meaning they carry two copies of it, face roughly four times the odds of developing renal amyloidosis compared to those with other genotypes.3PubMed. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever Male sex and the presence of arthritis attacks also raise the risk independently.
Interestingly, the mutations that cause FMF may have been preserved in Mediterranean populations because they once offered a survival advantage. Research on more than 2,300 Turkish individuals found genetic signatures of recent positive selection around FMF-associated mutations, and experiments showed that these mutations boost the immune response against Yersinia pestis, the bacterium responsible for plague.4PubMed Central. Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis Being a carrier of one FMF mutation (rather than two) may have helped ancestors survive plague epidemics, even though inheriting two copies causes disease.
TRAPS
Tumor necrosis factor receptor-associated periodic syndrome, or TRAPS, is caused by mutations in the TNFRSF1A gene, which encodes the receptor for TNF, a major inflammatory signaling molecule. Unlike FMF, TRAPS follows a dominant inheritance pattern, meaning a single mutated copy is enough to cause disease. Attacks tend to last longer than FMF episodes, often stretching from one to three weeks, and can include migratory muscle pain, a spreading rash, and swelling around the eyes. One likely mechanism involves defective shedding of the TNF receptor from cell surfaces. Normally, cells clip off part of the receptor and release it into the bloodstream, where it can soak up excess TNF and dampen inflammation. When this shedding process is impaired, the inflammatory signal keeps firing.5Current Opinion in Immunology. TNFRSF1A mutations and autoinflammatory syndromes
Cryopyrin-Associated Periodic Syndromes
CAPS is a spectrum of three conditions of increasing severity, all caused by gain-of-function mutations in the NLRP3 gene. These mutations cause excessive activation of a molecular complex called the inflammasome, which leads to overproduction of the inflammatory cytokine IL-1β.6PubMed Central. CAPS and NLRP3 The mildest form presents mainly as cold-triggered hives and fever. The most severe form, present from birth, causes chronic inflammation that can damage the brain, bones, and other organs if untreated. CAPS responds dramatically to drugs that block IL-1, which makes sense given the central role of IL-1β in driving the disease.
Mevalonate Kinase Deficiency
Formerly known as hyper-IgD syndrome (HIDS), this condition is caused by mutations in the MVK gene, which encodes an enzyme involved in cholesterol and isoprenoid production.7Nature Genetics. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome When this enzyme’s activity drops, the resulting metabolic imbalance triggers inflammation. The most common mutation, V377I, leaves the enzyme partially functional, producing a milder disease course.8PubMed. Characterization of mevalonate kinase V377I, a mutant implicated in defective isoprenoid biosynthesis and HIDS/periodic fever syndrome Fever episodes often begin in infancy and come with swollen lymph nodes, abdominal pain, joint pain, and skin rashes. Attacks typically last four to six days and can be triggered by vaccinations, infections, or physical stress.
PFAPA Syndrome, the Most Common Periodic Fever in Children
PFAPA stands for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis, which translates to recurring fever with mouth sores, sore throat, and swollen neck lymph nodes. Unlike the syndromes above, PFAPA has no known single-gene cause and is not considered a hereditary disease, though there is some evidence of familial clustering. It is the most common periodic fever syndrome seen in pediatric clinics, and it typically begins before age five.9PubMed Central. Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome (PFAPA): A Clinical Challenge for Primary Care Physicians and Rheumatologists
The episodes are strikingly predictable, often arriving like clockwork every three to six weeks. Each episode lasts a few days, the child looks completely healthy between attacks, and growth and development are normal. Because the symptoms mimic a throat infection, many children go through multiple rounds of unnecessary antibiotics before anyone considers PFAPA. In one cohort study, children experienced a median of 60 fever days per year before diagnosis, and 40% received more than five courses of antibiotics annually.10PubMed Central. Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome (PFAPA): A Clinical Challenge for Primary Care Physicians and Rheumatologists One useful diagnostic clue: a single dose of a corticosteroid like prednisone will dramatically abort a PFAPA episode within hours, which doesn’t happen with an ordinary infection.
PFAPA generally resolves on its own by late childhood, but “benign” is not the right word for the experience of living with it. A study comparing quality-of-life scores found that children with PFAPA reported lower health-related quality of life than children with FMF, a lifelong genetic condition.11PubMed Central. Health-related quality of life in children with PFAPA syndrome The regular disruption to school, family routines, and social life takes a real toll, and the emotional weight of repeated unexplained fevers on both children and parents deserves more attention than it typically gets.
Tonsillectomy and Other Treatments for PFAPA
For families exhausted by the cycle of fever episodes, tonsillectomy is a surprisingly effective option. A Cochrane review combining trial data found that surgery probably reduces the frequency of PFAPA episodes from roughly one every two months to fewer than one every two years.12PubMed Central. Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA) When episodes did still occur after surgery, they were shorter, averaging under two days compared to about three and a half days without surgery. Children who had tonsillectomy were also less likely to need corticosteroid treatment afterward.
That said, the trials were small, with only a few dozen children in the surgical arms, so rare complications of surgery couldn’t be reliably tracked. A meta-analysis comparing all available treatment approaches found that tonsillectomy and corticosteroids showed similar effectiveness for resolving individual episodes, though surgery had the advantage of preventing future ones.13PubMed. PFAPA syndrome in children: A meta-analysis on surgical versus medical treatment The decision usually comes down to how frequently attacks occur, how much they disrupt the family’s life, and whether a given family is comfortable with the risks of surgery in a young child for a condition that will eventually resolve on its own.
Corticosteroids remain the main acute treatment. A single dose at the start of an episode can cut the fever short within hours. The catch is that some families report that steroid use actually shortens the interval between episodes, meaning the next attack arrives sooner. This creates a frustrating trade-off: the current episode ends quickly, but the next one comes earlier.
Emotional Stress as a Trigger
Beyond infections and vaccinations, emotional stress may play a role in triggering PFAPA flares. During the early COVID-19 pandemic, researchers surveyed families of children with PFAPA and found that during the more stressful period, nearly 39% of children had at least one attack in the preceding two weeks, compared with about 23% during a less stressful period. Emotional distress scores were also higher during the stressful period.14PubMed Central. PFAPA flares observed during COVID outbreak: can emotional stress trigger PFAPA attacks? A multicenter cohort study This is far from proof that stress alone causes attacks, but it fits with a broader pattern in autoinflammatory disease where the threshold for an episode seems to shift with the overall state of the immune system.
IL-1 Blockers and the Treatment Revolution
For the hereditary syndromes, the development of drugs that specifically block IL-1 has been transformative. Canakinumab, a monoclonal antibody against IL-1β, was tested in a large randomized trial across three conditions: colchicine-resistant FMF, MKD, and TRAPS. At 16 weeks, complete responses were seen in about 61% of patients with colchicine-resistant FMF, 35% of those with MKD, and 45% of those with TRAPS, compared with roughly 6-8% on placebo. When the dose was increased to 300 mg every four weeks, those response rates climbed to about 71%, 57%, and 73% respectively.15PubMed. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes Infections were the most common side effect, which makes intuitive sense given that these drugs suppress part of the immune response.
For patients who don’t respond to IL-1 blockade, or who have TRAPS that doesn’t respond well to standard approaches, other biologic agents are sometimes tried. Tocilizumab, which blocks IL-6 rather than IL-1, has been used successfully in individual TRAPS patients when both anti-TNF drugs and canakinumab had failed or proved inadequate.16PubMed Central. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report Long-term follow-up of such cases has been encouraging.17PubMed. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) These remain case reports and small series, not large trials, but they illustrate the expanding toolbox clinicians have for conditions that were essentially untreatable a generation ago.
The Diagnostic Delay Problem
One of the most frustrating aspects of periodic fever syndromes is how long it takes to get the right diagnosis. Data from the Eurofever registry, which tracks over 2,200 patients across 32 countries, shows a median diagnostic delay of about three years overall. For FMF, the delay is shorter, around two years, likely because awareness is higher in the populations most affected. For TRAPS and CAPS, the median delay stretches to nearly six years, and for MKD, about five years.18Annals of the Rheumatic Diseases. Diagnostic Delay in Systemic Autoinflammatory Disease: Preliminary Results from the Eurofever Registry Patients who developed complications had a median delay of over eight years, compared to about two and a half years for those without complications. That gap likely reflects a vicious cycle: the longer you go without treatment, the more inflammation accumulates, and the more likely complications become.
The delay happens for understandable reasons. These are rare diseases, and the symptoms, particularly recurring fever, overlap with dozens of more common conditions. Children get sent to ear-nose-throat specialists, immunologists, and infectious disease doctors before anyone thinks to consult a rheumatologist. In the PFAPA cohort mentioned earlier, only 45% of patients were referred to a rheumatologist first; the rest went to ENT specialists or immunologists.19PubMed Central. Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome (PFAPA): A Clinical Challenge for Primary Care Physicians and Rheumatologists Genetic testing can confirm a hereditary syndrome, but the decision to order it requires someone to think of the diagnosis first.
Amyloidosis and Kidney Damage
Across the hereditary periodic fever syndromes, the most serious long-term threat is secondary amyloidosis. Chronic inflammation drives the liver to produce large amounts of serum amyloid A (SAA), an acute-phase protein. Over years, fragments of SAA can misfold and deposit as insoluble fibrils in tissues, especially the kidneys. Once amyloid deposits build up enough, they cause progressive kidney damage that can lead to kidney failure.20PubMed Central. Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage
The risk varies by disease and genotype. FMF carries the highest risk among the hereditary periodic fever syndromes, and as noted above, the M694V mutation is particularly associated with amyloidosis. In one study of FMF patients, the M694V allele was found in 67% of those with amyloidosis but only 25% of those without it.21PubMed Central. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects The practical takeaway is that genotype matters for prognosis: knowing which specific mutations a patient carries helps clinicians estimate their risk and decide how aggressively to treat.
The good news is that effective treatment dramatically reduces amyloidosis risk. Colchicine for FMF and IL-1 blockers for TRAPS, CAPS, and MKD all work by suppressing the inflammation that generates SAA in the first place. Keeping SAA levels low is the single most important strategy for preventing organ damage.
Still’s Disease and the Boundary with Periodic Fevers
Still’s disease is an autoinflammatory condition that overlaps with periodic fever syndromes in its pattern of spiking fevers, rash, joint inflammation, and elevated inflammatory markers. When it occurs in children, it’s called systemic juvenile idiopathic arthritis (sJIA); in adults, it’s called adult-onset Still’s disease (AOSD). A 2024 analysis supporting European guidelines concluded that these are really the same disease presenting at different ages, with nearly identical clinical features and similar diagnostic biomarker performance across both groups.22PubMed Central. Systemic juvenile idiopathic arthritis and adult-onset Still’s disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease The key biomarkers used to diagnose Still’s disease, especially ferritin and IL-18, distinguish it from both infections and other autoinflammatory conditions.
Still’s disease matters in the context of periodic fever syndromes because it sits at the edge of the category. It doesn’t follow the tidy pattern of a single gene mutation causing predictable episodes. Instead, it likely involves multiple genetic susceptibilities interacting with environmental triggers. Like the hereditary syndromes, it responds well to IL-1 blockade, which is one of the clues linking it to the same innate immune pathways.
VEXAS, an Adult-Onset Autoinflammatory Surprise
Most periodic fever syndromes begin in childhood, which can create a blind spot: adults presenting with new-onset inflammatory symptoms are rarely suspected of having an autoinflammatory disease. That changed in 2020 with the discovery of VEXAS syndrome, caused by somatic mutations in the UBA1 gene. Unlike the hereditary syndromes, VEXAS is not inherited. The mutations arise spontaneously in blood-forming stem cells during a person’s lifetime, usually in men over 50.23PubMed Central. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease
UBA1 encodes the main enzyme that starts the ubiquitin tagging process, a fundamental cellular housekeeping mechanism. When UBA1 is mutated, the affected blood cells can’t properly tag and dispose of damaged proteins, leading to widespread inflammation. The mutations are found in myeloid cells but not in lymphocytes or skin cells, which explains why the disease presents with systemic inflammation and blood abnormalities rather than problems in other tissues.24PubMed Central. VEXAS syndrome VEXAS is severe, often progressive, and resistant to many standard treatments. Its discovery has prompted clinicians to reconsider unexplained inflammatory conditions in older adults, and screening studies suggest it may be more common than initially thought.
Interferonopathies and the Expanding Map
The category of autoinflammatory disease keeps growing. A newer group called type I interferonopathies involves a different arm of innate immunity: the interferon pathway, which normally ramps up in response to viral infections. In these conditions, genetic mutations cause the interferon response to stay permanently switched on, producing chronic inflammation that can affect the skin, lungs, brain, and blood vessels. Recurrent fever is a common feature, but the pattern of organ involvement, particularly brain calcifications, skin lesions resembling chilblains, and interstitial lung disease, distinguishes these from the classic periodic fever syndromes.25PubMed Central. Type I Interferonopathies in Childhood
The interferonopathies matter here because they illustrate how the boundaries of “periodic fever syndrome” are still being redrawn. Twenty years ago, the list was short: FMF, TRAPS, CAPS, HIDS. Now it encompasses dozens of genetic conditions, acquired somatic mutations, and conditions of unknown genetic cause, all linked by the common thread of innate immune activation without infection. Genetic sequencing technology has been the main engine of this expansion, turning previously mysterious febrile illnesses into diagnosable, sometimes treatable, molecular entities.
The Financial and Family Burden
The economic cost of periodic fever syndromes goes well beyond medications. The same Italian cohort study that tracked PFAPA patients found that before diagnosis, the average annual direct medical cost per child was roughly €1,660, covering emergency department visits, hospitalizations, lab work, and unnecessary prescriptions. But the indirect costs to families, covering lost workdays, childcare disruptions, and travel to specialists, averaged about €5,800 per parent per year.26PubMed Central. Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome (PFAPA): A Clinical Challenge for Primary Care Physicians and Rheumatologists Nearly 38% of children needed emergency department visits, and over a third were hospitalized at least once during the diagnostic process. These numbers underscore why shortening the diagnostic delay isn’t just a medical priority but an economic one. Every month spent chasing the wrong diagnosis means more unnecessary antibiotics, more ER trips, and more days of school and work missed.